Welcome to our dedicated page for Regen Biopharma news (Ticker: RGBPP), a resource for investors and traders seeking the latest updates and insights on Regen Biopharma stock.
Regen BioPharma PFD A (RGBPP) is a preferred share class of Regen BioPharma, Inc., a publicly traded biotechnology company on the OTC Pink marketplace. Company news for RGBPP reflects developments at Regen BioPharma in immunology, immunotherapy, and its lead cell‑based therapeutic program, HemaXellerate.
News releases highlight Regen BioPharma’s efforts to advance HemaXellerate, a stem cell‑derived therapy designed to stimulate bone marrow regeneration and restore healthy blood cell production. The company reports FDA Investigational New Drug clearance for HemaXellerate and has discussed plans and preparations for a Phase I clinical trial in aplastic anemia, a rare and serious bone marrow disorder.
Investors following RGBPP news can also see updates on Regen BioPharma’s regulatory interactions, including submission of an Orphan Drug Application for HemaXellerate in aplastic anemia and the company’s process of addressing FDA comments on that application. Additional news items describe the exploration of chemotherapy‑induced bone marrow suppression as a second indication, positioning HemaXellerate as a potential multi‑lineage regenerative approach in oncology supportive care.
Beyond HemaXellerate, Regen BioPharma news covers its broader pre‑clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics, and small molecule drugs for cancer and autoimmune disorders. The company frequently uses Emerging Growth Conference presentations to discuss scientific progress, clinical plans, and programs such as DuraCAR, offering investors and analysts a forum to ask questions in real time.
For holders and prospective investors in RGBPP, this news feed provides a centralized view of Regen BioPharma’s scientific updates, clinical trial planning, orphan drug strategy, and capital markets communications related to its immunology and immunotherapy focus.
Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP) is set to present at the Emerging Growth Conference on February 22, 2023, from 2:40 to 2:50 PM Eastern Time. This live event will provide a platform for interaction with CEO Dr. David Koos, where shareholder questions will be addressed. Key discussion points include updates on a pending reverse stock split and future financing plans. Registration is available for real-time participation and an archived webcast will also be accessible post-event. The conference showcases companies in growth sectors and aims to connect them with investors.
Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP) invites investors to its live presentation at the Emerging Growth Conference on February 8, 2023. The interactive session will provide insights on the company's strategic plans, drug pipeline, and upcoming 1-for-1500 reverse stock split effective March 6, 2023. CEO Dr. David Koos will address shareholder questions during the event.
Regen BioPharma is focused on advancing therapies for cancer and autoimmune disorders through pre-clinical and Phase I/II clinical trials. The conference presentation is scheduled from 2:20 - 2:50 PM Eastern Time. An archived webcast will be available post-event.
Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP) will present at the Emerging Growth Conference on January 25, 2023, from 3:30 - 3:40 PM Eastern. This online event allows shareholders and the investment community to engage with CEO Dr. David Koos in real time. The company aims to update stakeholders on recent intellectual property and respond to questions during the session. Attendees can register for the event at the [official registration link](https://goto.webcasts.com/starthere.jsp?ei=1575092&tp_key=9111d280ed&sti=rgbp). An archived version of the presentation will also be available on [EmergingGrowth.com](http://EmergingGrowth.com).
Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP) has filed a provisional patent application focused on using survivin-engineered dendritic cells and exosomes to enhance anti-cancer immunity. This approach aims to improve the immune system's ability to target and destroy survivin-expressing tumor cells while sparing healthy tissue. The company draws on prior work with DCellVax for breast cancer treatment and is positioned to diversify its portfolio in the expanding immunotherapy market, which is projected to reach $100 billion globally. CEO David Koos emphasized the potential for new revenue streams through this innovative strategy.
Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP) announced the addition of Dr. Ravinder Reddy and Dr. Mohammad Haris to its Scientific Advisory Board, enhancing its expertise in immunotherapy. Dr. Reddy, a leading researcher in cancer imaging, has over 200 peer-reviewed publications and numerous awards. Dr. Haris specializes in metabolic imaging technologies for cancer and neurological disorders with over 100 publications. CEO David Koos emphasized the importance of their expertise as the company advances its CAR T-cell and immunotherapy initiatives.
Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP) invites investors and analysts to attend its interactive online presentation at the Emerging Growth Conference on November 30, 2022, from 1:45 to 2:00 PM Eastern Time.
The CEO, Dr. David Koos, will provide updates on their CAR T-cell development program and encourage live Q&A participation. If unable to attend, an archived webcast will be available. Regen BioPharma focuses on immunotherapy, advancing mRNA and small molecule therapies for cancer and autoimmune disorders.
Regen BioPharma (OTC PINK: RGBP, RGBPP) is advancing a novel CAR-T therapy, named DuraCAR, designed to treat solid tumors. This innovative approach targets the NR2F6 immune checkpoint, which can suppress T cell activity. By inhibiting NR2F6, DuraCAR aims to prevent T cell exhaustion, enabling enhanced tumor destruction. The company anticipates further experimental results in the coming months to refine this therapeutic approach. Regen BioPharma focuses on immunology and immunotherapy development, striving to address significant challenges in cancer treatment.
Regen BioPharma, Inc. (OTC-PINK: RGBP, RGBPP) will present at the Emerging Growth Conference on November 9, 2022, from 1:45 - 2:15 PM Eastern Time. This live, interactive event allows investors to engage with CEO Dr. David Koos in real time. The company focuses on biotechnology, advancing therapies including RNA vaccines and small molecule drugs. Registration is available via the conference website, and an archived version will be accessible afterward. This event aims to enhance communication between Regen BioPharma and its shareholders.
Regen BioPharma, Inc. (OTC PINK: RGBP) has initiated a program to expedite the clinical development of its NR2F6 therapies by integrating modified mRNA technology with its existing siRNA intellectual property. The company has submitted an Investigational New Drug Application (IND#16928) for its drug tCellVax, designed to silence NR2F6 in human immune cells to enhance their ability to combat cancer. Regen has engaged Dyo Biotechnologies for support in this development, and is developing a new patent application to protect its innovations.
Oncology Pharma (OTC PINK:ONPH) and Regen BioPharma (OTC PINK:RGBP, RGBPP) announced a collaboration to accelerate the development of therapeutic mRNA vaccines for treating pancreatic cancer. ONPH has exclusive rights to the commercial development of these vaccines, which utilize modified mRNA to boost the immune response against cancer. The joint effort will focus on IND-enabling studies, with Regen providing scientific expertise. The project faces contingencies including securing financing and final agreement terms. The advancement of this technology could positively impact pancreatic cancer treatment.
FAQ
What is the current stock price of Regen Biopharma (RGBPP)?
What is the market cap of Regen Biopharma (RGBPP)?
